Document is current

Article History

Received: 3 September 2024

Accepted: 12 December 2024

First Online: 23 December 2024

Declarations

:

: All study animals were treated according to the Association for Research in Vision and Ophthalmology Statement for the Use of Animals in Ophthalmic and Vision Research. The Animal Experiment Committee of Shin Nippon Biomedical Laboratories, Ltd., (2438 Miyanouracho, Kagoshima City, Kagoshima Prefecture) approved the study in advance ((1) Title of the approved project; Single Subretinal Dose Retinal Protection Efficacy Study for PAL-222 in RCS Rats, (2) Name of the institutional approval committee or unit; The Animal Experiment Committee of Shin Nippon Biomedical Laboratories, Ltd., (3) Approval number; SBL469-010, (4) Date of approval; 5/23/2022). The testing facility was accredited by AAALAC International. Human cells were managed according to the tenets of the Declaration of Helsinki. This study does not report on or involve the use of any human data.

: Not applicable.

: NN and TY are advisors and shareholders of PharmaBio Corporation. Funders played a role in the conduct of the study, collection of data, management of the study, analysis of data, interpretation of data, or preparation of the manuscript.